- Home
- BIIB vs TTWO Comparison
BIIB vs TTWO Comparison
Compare BIIB & TTWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- TTWO
- Stock Information
- Founded
- BIIB 1978
- TTWO 1993
- Country
- BIIB United States
- TTWO United States
- Employees
- BIIB N/A
- TTWO N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- TTWO Computer Software: Prepackaged Software
- Sector
- BIIB Health Care
- TTWO Technology
- Exchange
- BIIB Nasdaq
- TTWO Nasdaq
- Market Cap
- BIIB 25.1B
- TTWO 32.6B
- IPO Year
- BIIB 1991
- TTWO 1997
- Fundamental
- Price
- BIIB $149.02
- TTWO $185.39
- Analyst Decision
- BIIB Buy
- TTWO Strong Buy
- Analyst Count
- BIIB 26
- TTWO 20
- Target Price
- BIIB $248.00
- TTWO $200.11
- AVG Volume (30 Days)
- BIIB 1.6M
- TTWO 1.5M
- Earning Date
- BIIB 02-11-2025
- TTWO 02-06-2025
- Dividend Yield
- BIIB N/A
- TTWO N/A
- EPS Growth
- BIIB 10.05
- TTWO N/A
- EPS
- BIIB 11.06
- TTWO N/A
- Revenue
- BIIB $9,607,500,000.00
- TTWO $5,457,000,000.00
- Revenue This Year
- BIIB N/A
- TTWO $7.24
- Revenue Next Year
- BIIB N/A
- TTWO $45.83
- P/E Ratio
- BIIB $13.47
- TTWO N/A
- Revenue Growth
- BIIB N/A
- TTWO 0.35
- 52 Week Low
- BIIB $145.07
- TTWO $135.24
- 52 Week High
- BIIB $268.30
- TTWO $191.91
- Technical
- Relative Strength Index (RSI)
- BIIB 32.44
- TTWO 54.70
- Support Level
- BIIB $145.07
- TTWO $179.00
- Resistance Level
- BIIB $149.92
- TTWO $188.40
- Average True Range (ATR)
- BIIB 3.81
- TTWO 3.60
- MACD
- BIIB 0.05
- TTWO -1.32
- Stochastic Oscillator
- BIIB 22.51
- TTWO 49.50
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About TTWO Take-Two Interactive Software Inc.
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.